Genprex, Inc. Gains 21.69%
Fri 21 Feb 20 at 05:30 PM
Genprex, Inc. (GNPX:NASDAQ) rocketted at $5.33, representing a gain of 21.7%. The stock appeared on our News Catalysts scanner on Tue 11 Feb 20 at 02:17 PM in the 'AGREEMENT' category. From Thu 30 Jan 20, the stock recorded 57.14% Up Days and 53.33% Green Days
About Genprex, Inc. (GNPX:NASDAQ)
Genprex Inc is a clinical stage gene therapy company. It develops therapies that carry cancer-fighting genes. Its initial product candidate is Oncoprex.
Top 10 Gainers:
- Tocagen Inc. (TOCA:NASDAQ), 111.11%
- Trans World Entertainment Corporation (TWMC:NASDAQ), 50.86%
- Unit Corporation (UNT:NYSE), 37.02%
- Celldex Therapeutics, Inc. (CLDX:NASDAQ), 35.24%
- Ducommun Incorporated (DCO:NYSE), 33.09%
- Eldorado Gold Corporation (EGO:NYSE), 32.05%
- Avadel Pharmaceuticals plc (AVDL:NASDAQ), 32.02%
- Genprex, Inc. (GNPX:NASDAQ), 21.69%
- Kirkland's, Inc. (KIRK:NASDAQ), 20.66%
- IGM Biosciences, Inc. (IGMS:NASDAQ), 20.25%